Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
THE WOODLANDS, Texas, Feb. 25, 2009 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human...
-
THE WOODLANDS, Texas, Feb. 18, 2009 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) will release its fourth quarter and year end 2008 financial results on Wednesday, February 25, 2009...
-
THE WOODLANDS, Texas, Jan. 22, 2009 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human...
-
THE WOODLANDS, Texas, Jan. 12, 2009 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human...
-
THE WOODLANDS, Texas, Jan. 8, 2009 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer,...
-
* No Significant Cognitive Effects Observed in Subjects with Age-Associated Memory Impairment * Future LX6171 Clinical Development Plans to be Re-evaluated * Phase 2 Development Resources to...
-
* New Oral Small Molecule Drug Candidate for Type 2 Diabetes * SGLT2 Inhibition Shown to Reduce Blood Glucose Levels and Body Weight * Phase 1 Clinical Trials to Begin Following FDA...
-
THE WOODLANDS, Texas, Nov. 25, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) announced today that it will hold its Annual R&D Day on Tuesday, December 2, 2008 from 8:00 a.m....
-
THE WOODLANDS, Texas, Nov. 24, 2008 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX) announced today that members of Lexicon senior management will present at the following healthcare...
-
* Drug Candidate Will Advance to Phase 2 Clinical Trial in Carcinoid Patients * Potent Reduction in Serotonin Achieved * Drug Candidate Being Developed Under Fast Track Status From FDA THE...